pralurbactam
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Oct 31, 2024 (NCT06633718)
Timeline
Indications
Mechanism of action
- ADC-14 proteinINHIBITOR
adc-14 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
N=C(N)NOCCONC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O- Mol. weight
- 382.36 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314477 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07124468 | Phase 1 | Sep 13, 2025 | Qilu Pharmaceutical Co., Ltd. |
| NCT07089186 | Phase 3 | Apr 12, 2025 | Qilu Pharmaceutical Co., Ltd. |
| NCT06633718 | Phase 3 | Oct 31, 2024 | Qilu Pharmaceutical Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Qilu Pharmaceutical Co., Ltd. | For profit | 3 | 3 | 2 | 2024 |
1 organizations
Page 1 / 1